Compare MFC & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFC | TAK |
|---|---|---|
| Founded | 1887 | 1781 |
| Country | Canada | Japan |
| Employees | 37000 | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.5B | 69.1B |
| IPO Year | 2002 | 2007 |
| Metric | MFC | TAK |
|---|---|---|
| Price | $41.04 | $21.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $24.48 |
| AVG Volume (30 Days) | 1.8M | ★ 3.1M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | ★ 3.31% | 1.12% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $91.93 | $4.79 |
| Revenue Next Year | N/A | $2.44 |
| P/E Ratio | ★ $16.52 | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.66 | $14.16 |
| 52 Week High | $46.19 | $21.86 |
| Indicator | MFC | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 31.75 | 69.50 |
| Support Level | $39.48 | $17.66 |
| Resistance Level | $41.43 | N/A |
| Average True Range (ATR) | 0.82 | 0.33 |
| MACD | -0.36 | -0.01 |
| Stochastic Oscillator | 1.33 | 82.22 |
Manulife Financial is one of the Big Three Canadian life insurers. The firm provides life insurance, annuities, asset management, and wealth management products to individuals and group customers in Canada, the United States, and Asia. The Canadian business segment contributes approximately 21% of 2025 adjusted earnings. The Asia segment operates across 12 countries and contributes around 38% of earnings, with a significant presence in Hong Kong and Singapore. The US business, which primarily operates under the John Hancock brand, contributes about 16% of earnings. Manulife's global asset and wealth management business contributes approximately 25% of its earnings. The firm had around CAD 1.2 trillion in assets under management and administration as of the end of June 2026.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.